title: miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants.
abstract: The serotonin transporter (SERT) ensures the recapture of serotonin and is the pharmacological target of selective serotonin reuptake inhibitor (SSRI) antidepressants. We show that SERT is a target of microRNA-16 (miR-16). miR-16 is expressed at higher levels in noradrenergic than in serotonergic cells; its reduction in noradrenergic neurons causes de novo SERT expression. In mice, chronic treatment with the SSRI fluoxetine (Prozac) increases miR-16 levels in serotonergic raphe nuclei, which reduces SERT expression. Further, raphe exposed to fluoxetine release the neurotrophic factor S100β, which acts on noradrenergic cells of the locus coeruleus. By decreasing miR-16, S100β turns on the expression of serotonergic functions in noradrenergic neurons. Based on pharmacological and behavioral data, we propose that miR-16 contributes to the therapeutic action of SSRI antidepressants in monoaminergic neurons.
authors.affiliation: Cellules Souches, Signalisation et Prions, INSERM U747, Université Paris Descartes, 75006 Paris, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Baudry
authors.forename: Sophie
authors.initials: S
authors.lastname: Mouillet-Richard
authors.forename: Benoît
authors.initials: B
authors.lastname: Schneider
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Launay
authors.forename: Odile
authors.initials: O
authors.lastname: Kellermann
mesh_terms: D020413:3' Untranslated Regions; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D002460:Cell Line; D003863:Depression; D005473:Fluoxetine / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D006367:HeLa Cells; D006801:Humans; D008125:Locus Coeruleus / Q000378:metabolism; D051379:Mice; D035683:MicroRNAs / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*; D009414:Nerve Growth Factors / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009638:Norepinephrine / Q000378:metabolism; D014176:Protein Biosynthesis; D011903:Raphe Nuclei / Q000187:drug effects / Q000378:metabolism*; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics* / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D015854:Up-Regulation
chemical_list: D020413:3' Untranslated Regions; D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D035683:MicroRNAs; D009414:Nerve Growth Factors; D009638:Norepinephrine; D064568:S100 Calcium Binding Protein beta Subunit; D009418:S100 Proteins; D012701:Serotonin; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors; C522604:Mirn16 microRNA, mouse; C493231:Slc6a4 protein, mouse